Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enrolled in the open-label extension study are presented.



Remission and response per the full Mayo score (FMS) and the partial Mayo score (PMS), remission per the Inflammatory Bowel Disease Questionnaire (IBDQ) score, corticosteroid-free remission, and mucosal healing were assessed up to week 196 (week 208 for remission/response per PMS) of adalimumab treatment in patients who received one or more doses of adalimumab with use of a hybrid nonresponder imputation (hNRI) method. Nonresponder imputation was used for missing data up to the latest possible follow-up date for each patient, followed by observed case. Adalimumab trough concentrations were reported from week 52 to week 196 of treatment. Treatment-emergent adverse events were reported for all adalimumab-treated patients.



Two hundred sixty-six patients received adalimumab. At week 196 of treatment, remission and response rates per FMS, remission and response rates per PMS, remission rate per IBDQ score, mucosal healing rate, and corticosteroid-free remission rate were 19.2%, 32.2%, 22.5%, 32.5%, 33.1%, 30.5% (hNRI), and 40.5% (17/42; as observed), respectively. Serum adalimumab concentrations remained constant in patients receiving 40 mg every other week but increased in patients who underwent dose escalation. The safety profile was consistent with that in the 52-week study.



The efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis was maintained for up to 4 years of treatment. No new safety signals were observed.
Toho University Medical Center Sakura Hospital, Chiba, Japan.
Yasuo
Y
Suzuki
IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan.
Satoshi
S
Motoya
Hamamatsu South Hospital, Shizuoka, Japan.
Hiroyuki
H
Hanai
IBD Centre, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan. thibi@insti.kitasato-u.ac.jp.
Toshifumi
T
Hibi
Hyogo College of Medicine Hospital, Nishinomiya, Hyogo, Japan.
Shiro
S
Nakamura
AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Andreas
A
Lazar
AbbVie Inc., North Chicago, IL, USA.
Anne Martin
AM
Robinson
AbbVie Inc., North Chicago, IL, USA.
Martha
M
Skup
AbbVie Inc., North Chicago, IL, USA.
Nael Mohamed
NM
Mostafa
AbbVie Inc., North Chicago, IL, USA.
Bidan
B
Huang
AbbVie Inc., North Chicago, IL, USA.
Roopal
R
Thakkar
Department of Gastroenterology, Tokyo Medical and Dental University, Tokyo, Japan.
Mamoru
M
Watanabe
D000068879:Adalimumab / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000068879:Adalimumab
Clinical remission; Tumor necrosis factor